Ram Kumar 
India’s primary market has been highly active, with numerous companies making their stock market debuts. Several newly listed firms have delivered stellar returns to investors, while a few have posted modest or even negative performances. Here’s a detailed look at the NSE IPO data highlighting the gainers, losers, and trends as of September 15, 2025.
Anondita Medicare Leads the IPO Rally
Among the recent listings, Anondita Medicare Limited has emerged as a top performer. The company, which listed on September 1, 2025, at an issue price of ₹145, closed its debut at ₹289.25, providing an impressive 99.48% listing gain. Its momentum has continued, with the stock currently trading at ₹407.00, marking a massive 180.69% overall gain from its issue price.
This exceptional performance reflects strong investor confidence in the healthcare sector, with demand for pharmaceutical and medical supply companies continuing to rise.
Current Infraprojects Delivers Strong Gains
Current Infraprojects Limited, listed on September 3, 2025, at an issue price of ₹80, delivered a significant 90.94% listing day gain, closing at ₹152.75. While the stock has since settled at ₹131.90, it still offers investors a solid 64.88% return from its issue price. Infrastructure plays are benefiting from the government’s ongoing push for capital expenditure and development projects, which is being reflected in investor sentiment.
BlueStone Jewellery Shines Bright
BlueStone Jewellery and Lifestyle Limited entered the market on August 16, 2025, at an issue price of ₹517 per share. On its listing day, the stock closed at ₹546.00, a 5.61% premium. However, its current trading price has surged to ₹636.70, translating to a strong 23.15% overall gain. This performance highlights investor appetite for branded lifestyle and jewelry companies, especially ahead of the festive season.
Other Notable Performers
- Optivalue Tek Consulting Limited, listed on September 10, saw a 22.14% listing gain and is currently up 21.43% overall.
- Amanta Healthcare Limited delivered a 12.50% listing gain, with the stock currently up 8.45% from its issue price.
- Sattva Engineering Construction Limited has given investors a steady 37.33% overall return, supported by a positive infrastructure outlook.
- Anlon Healthcare Limited offered modest debut gains but has since rallied to deliver nearly 20% return.
- Vigran Retail Limited has provided a 2.00% gain, closing at ₹361.85.
- Patel Retail Limited is trading at ₹254.25, showing a -0.29% decline from its issue price of ₹255.00.
Weak Performers: ARC Insulation Faces Pressure
Not all IPOs have sustained momentum. ARC Insulation & Insulators Limited, which listed at ₹125, closed its debut session with a 10.20% gain at ₹137.75. However, the stock has since fallen to ₹105.35, reflecting a 15.72% loss from its issue price. Similarly, Patel Retail Limited is trading slightly below its issue price, with a 0.29% decline.
Key Takeaways for Investors
The recent IPO trend highlights that:
- Healthcare and infrastructure companies are witnessing strong demand and delivering significant returns.
- Consumer-focused brands like BlueStone are gaining traction, riding on robust domestic demand.
- Not all IPOs guarantee profits, as seen with ARC Insulation & Insulators and Patel Retail, reminding investors of the inherent risks in primary markets.
Final Word
The Indian IPO market in August and September 2025 has offered both spectacular winners and cautionary reminders. While companies like Anondita Medicare, Current Infraprojects, and BlueStone have rewarded investors, others have underperformed. Investors should carefully evaluate fundamentals, sectoral outlook, and long-term growth potential before subscribing to upcoming IPOs.
Disclaimer: This article is for informational purposes only and is based on a screenshot of data from a specific moment in time (September 15, 2025). The data and performance metrics cited are reflective of a particular date and may not be indicative of future market performance. Investors are advised to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The information provided does not constitute financial advice.
Author Bio
